REMARKS

Favorable reconsideration of this application in light of the preceding amendments and the following remarks is respectfully requested.

No claims having been canceled or added, the Applicants respectfully submit that claims 1-22 remain properly under consideration in this application.

Support for the corrected sequence listing is found in the sequence listing as originally filed in this application. The Applicants respectfully submit that the original Sequence Listing was inadvertently generated using PatentIn 2.1, rather than the current PatentIn 3.3, resulting in numerous errors with regard to the format of the listing. The Applicants respectfully submit that the actual nucleotide and amino acid sequences provided in the corrected Sequence Listing are intended to be and are believed to be identical to those provided in the original Sequence Listing. The Applicants further note that no errors were detected during generation or during verification of the computer readable format file from the enclosed CD using Checker 4.2.2.

CONCLUSION

In view of the above remarks and amendments, the Applicants respectfully submit that the present application in condition for examination and allowance. A notice to that effect is respectfully requested.

If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to contact the undersigned.

Attorney Docket No. 12480-000066/US Application No. 10/509,248

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge any underpayment or non-payment of any fees required under 37 C.F.R. §§ 1.16 or 1.17, or credit any overpayment of such fees, to Deposit Account No. 08-0750, including, in particular, extension of time fees.

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C.

Bv

Donald J. Daley, Reg. No. 34,31

P.O. Box 8910 Reston, VA 20195

(703) 668-8000

الار DJD/GPB:ewd

Enclosure:

Copy of Sequence Listing

Computer Readable Format (CRF) Sequence Listing (CD)

Statement Under 37 C.F.R. § 1.821(f)